Clinical Scorecard: Hypophosphatemic Osteomalacia and Osteoporosis Associated with Adefovir Dipivoxil: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Adefovir dipivoxil-induced hypophosphatemic osteomalacia and postmenopausal osteoporosis
Key Mechanisms
ADV nephrotoxicity causing Fanconi syndrome leading to renal phosphate wasting and hypophosphatemia resulting in osteomalacia; underlying risk factors contributing to persistent low BMD
Target Population
Postmenopausal women receiving long-term adefovir dipivoxil therapy for chronic hepatitis B
Care Setting
Orthopedic and nephrology clinical settings managing bone pain, metabolic abnormalities, and osteoporosis
Discontinuation of ADV and supplementation with vitamin D and phosphate can normalize biochemical parameters and improve bone pain.
Persistent low BMD after osteomalacia correction may indicate concomitant postmenopausal osteoporosis requiring further evaluation and anti-osteoporotic treatment.
Guideline-Based Recommendations
Diagnosis
Evaluate patients on long-term ADV presenting with bone pain for hypophosphatemia, renal tubular acidosis, and elevated fractional excretion of phosphate.
Exclude other causes of bone disease such as multiple myeloma, rheumatoid arthritis, and bone metastases.
Use imaging (DXA, MRI, CT, bone scintigraphy) to assess bone density and fractures.
Management
Discontinue adefovir dipivoxil upon diagnosis of drug-induced hypophosphatemic osteomalacia.
Administer phosphate and vitamin D supplementation to correct metabolic abnormalities.
Initiate anti-osteoporotic pharmacotherapy (e.g., denosumab) after osteomalacia correction if low BMD persists.
Monitoring & Follow-up
Monitor biochemical parameters including serum phosphate, calcium, alkaline phosphatase, and renal function.
Follow-up bone mineral density assessments to evaluate improvement and detect persistent osteoporosis.
Assess clinical symptoms such as bone pain and mobility regularly.
Risks
Prolonged ADV therapy increases risk of Fanconi syndrome and hypophosphatemic osteomalacia.
Misdiagnosis as primary osteoporosis may delay appropriate treatment.
Persistent low BMD after osteomalacia correction increases fracture risk.
Patient & Prescribing Data
67-year-old postmenopausal woman with chronic hepatitis B on long-term ADV therapy
Discontinuation of ADV combined with phosphate and vitamin D supplementation improved biochemical and clinical parameters; denosumab initiated for persistent osteoporosis.
Clinical Best Practices
Consider drug-induced osteomalacia in patients on long-term ADV presenting with bone pain and low BMD.
Correct metabolic abnormalities before diagnosing and treating primary osteoporosis.
Use a multidisciplinary approach including nephrology, orthopedics, and endocrinology for comprehensive management.
Regularly monitor bone health and renal function in patients receiving nucleotide analogues like ADV.
